<![CDATA[Englumafusp Alfa Combo Shows Encouraging Activity in B-Cell Lymphoma]]>

Phase 1positiveenglumafusp alfaglofitamabPositive

AI Analysis

Summary

Englumafusp alfa combined with glofitamab demonstrated a 68.7% overall response rate in a Phase 1 trial of heavily pretreated patients with aggressive B-cell non-Hodgkin lymphoma, showing encouraging activity in this patient population.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

68.7% overall response rate in heavily pretreated aggressive B-cell non-Hodgkin lymphoma

Importance:5/10

Sentiment:

0.70

oncologyB-cell lymphomacombination therapyPhase 1 datahematologic malignancy

Read the original article

Published by Cancer Network on July 16, 2026 7:00 PM

Read Original